In 2025, Serbia’s pharmaceutical and medical supplies sector emerged as a robust segment within the national economy, demonstrating significant financial resilience amid broader economic challenges. While other sectors, such as export manufacturing and construction, faced margin pressures and contractions, pharmaceutical firms maintained steady revenues and profitability. This stability can be attributed to regulated demand for essential products and a diverse export portfolio, which typically perform well during periods of economic stress.
The landscape of Serbia’s pharmaceutical industry features a combination of domestic generic manufacturers, regional distribution networks, and an increasing presence of contract manufacturing for international brand owners. In 2025, revenues within the sector grew modestly, generally in the range of 3–6% year-on-year. This growth was primarily driven by volume increases and selective price adjustments rather than significant market expansion. Domestic consumption remained stable, bolstered by public procurement and healthcare spending, while exports to CEFTA markets, the European Union, and select non-European destinations contributed to incremental revenue increases.
A key strength of the sector has been its margin durability. Earnings before interest, taxes, depreciation, and amortization (EBITDA) margins for established manufacturers and distributors ranged from 15% to 25%, influenced by product mix and export exposure. Companies focused on pure generics and vertically integrated distribution operated at the lower end of this spectrum, whereas those involved in contract manufacturing and specialty medicines achieved margins exceeding 20%. Despite rising labor and compliance costs, net profit margins remained robust at approximately 8–12%.
Cost structures within the pharmaceutical sector demonstrated greater resilience compared to many other manufacturing industries. Although raw material and active pharmaceutical ingredient prices fluctuated throughout 2025, long-term supply contracts helped mitigate volatility. Labor costs increased by around 9–11%, driven by competition for skilled professionals; however, given that labor constitutes a smaller portion of total costs compared to services, companies managed to sustain their margins through operational efficiency.
Investment in capital remains moderate within the sector. Manufacturers continued to allocate funds toward equipment upgrades and compliance with quality standards while maintaining capital expenditure intensity at about 4–6% of revenues. This represents a decrease from previous expansion phases. New investments were primarily directed towards automation and quality systems aligned with EU regulations rather than increasing production capacity.
Working capital dynamics favored stability in pharmaceutical distribution due to predictable payment cycles associated with public healthcare procurement. Receivable periods generally ranged from 45 to 75 days, while inventory turnover was closely monitored due to expiry risks. Consequently, net working capital typically absorbed between 15% and 20% of annual revenues—significantly lower than in sectors like agro-processing or automotive supply chains.
The balance sheets across the pharmaceutical sector exhibited conservative characteristics. Net debt to EBITDA ratios typically fell between 1.0x and 2.0x, reflecting consistent cash generation amidst cautious expansion approaches. Although rising interest rates increased financing costs, debt service remained well-covered with interest-coverage ratios often surpassing 6x EBITDA. Financial institutions regarded pharmaceutical companies as low-risk borrowers, ensuring continued access to credit even under tighter conditions.
Regulatory compliance posed both a cost burden and a competitive barrier within the industry. Adherence to EU-aligned good manufacturing practices (GMP), pharmacovigilance regulations, and traceability requirements incurred recurring overheads estimated between €100,000 and €500,000 annually for mid-sized manufacturers. While these costs were considerable, they also protected established firms by raising entry barriers for new competitors.
Pricing dynamics in the sector remained constrained yet predictable due to domestic price controls on publicly reimbursed medicines; however, export pricing strategies provided necessary flexibility. Companies with diversified revenue streams managed to offset lower domestic margins with higher profitability from exports.
The medical supplies and devices segment represented a smaller but expanding niche within the industry. Revenue growth in this area outpaced the overall sector average at rates between 6% and 10%, supported by advancements in healthcare systems and private healthcare initiatives. Margins varied widely but could exceed 20% for specialized products with limited competition.
From an investment perspective, the pharmaceutical sector presented moderate growth potential alongside high resilience. Equity returns in 2025 were largely influenced by cash yields rather than multiple expansions; acquisition transactions suggested equity internal rates of return between 12% and 16%. Strategic buyers prioritized compliance maturity and export readiness over mere scale when considering acquisitions.
The primary strategic risk identified was related to policy changes regarding pricing formulas or reimbursement timelines that might affect cash flow timing; however, the diversified customer base helped mitigate this risk throughout the year.
By year-end 2025, pharmaceuticals and medical supplies had established themselves as a stabilizing force within Serbia’s corporate landscape. Financial performance was characterized by predictability in revenues and resilience in margins against a backdrop of rising compliance costs.
Looking forward, gradual consolidation within the sector is anticipated alongside increased specialization rather than rapid growth. Companies that focus on regulatory excellence and niche markets are likely to maintain returns above their cost of capital while those dependent solely on domestic markets may face stagnation yet remain solvent.
